1,887
Participants
Start Date
October 31, 2007
Primary Completion Date
November 30, 2009
Study Completion Date
November 30, 2009
EE20/DRSP (BAY86-5300)
Combination tablet containing 0.02 mg ethinyl estradiol as betadex clathrate and 3.0 mg drospirenone
EE20/DRSP (BAY86-5300)
Combination tablet containing 0.02 mg ethinyl estradiol as betadex clathrate and 3.0 mg drospirenone
EE20/DRSP (YAZ, BAY86-5300)
Fixed package per cycle containing combination tablets containing 0.02 mg ethinyl estradiol as betadex clathrate and 3.0 mg drospirenone (24 per cycle) + tablets without active substance (4 per cycle)
Rochester
Pittsburgh
Jenkintown
Philadelphia
Richmond
Richmond
Winston-Salem
Durham
New Bern
Columbia
Mt. Pleasant
Decatur
Atlanta
Jacksonville
Pembroke Pines
Coral Gables
South Miami
North Miami
Miami
Plantation
West Palm Beach
Lake Worth
St. Petersburg
Clearwater
Naples
Crystal River
Brooksville
Montgomery
Nashville
Chattanooga
Knoxville
Memphis
Lexington
Columbus
Cleveland
Newburgh
Paw Paw
Bismarck
Chicago
Champaign
Chesterfield
Kansas City
Wichita
Lincoln
Marrero
Oklahoma City
Dallas
Colleyville
Houston
Houston
Corpus Christi
Greenwood Village
Littleton
Denver
Colorado Springs
Idaho Falls
Boise
Boise
West Jordan
Phoenix
Mesa
Mesa
Chandler
Tempe
Tucson
Tucson
Las Vegas
LasVegas
Las Vegas
Beverly Hills
Pacific Palisades
San Diego
San Diego
Santa Ana
Vallejo
Portland
Seattle
Spokane
Anaheim
Waterbury
Boynton Beach
Moorestown
New Brunswick
Portland
Jackson
Lead Sponsor
Bayer
INDUSTRY